SYDNEY, Sept. 14, 2018 /PRNewswire/ — Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
The study has challenged the long held assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery.
“We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Until now schizophrenia research focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. New molecular techniques allowed the team to identify a fourth cell, the macrophage, a type of immune cell in brain tissue of people with schizophrenia who show high levels of inflammation.
“Immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now,” said Professor Shannon Weickert.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia.”
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.”
“We think this may cause the endothelial cells to capture the immune cells when they travel by. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder,” said Professor Shannon Weickert.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Don’t walk alone, journey with someone. What does it mean to be Malaysian? We may be fit and healthy today, so put that health towards doing something good.
Think of your neighbour living next door that may be bound to her wheelchair, a friend going through a rough patch in life, a senior citizen feeling lonely. Everyone needs someone to journey with them, and we can. Not everyone can run but anyone can walk with someone in need of a friend, companion and love. You know you can run, but choose to walk with someone that may just need your encouragement.
When I am weak, you are strong. Walk with us, Walk for Malaysians.
Welcome to the second #Move8 Walkathon! Participation fee is RM80 until 31 October 2018; normal fee is RM100. Sign up at www.move8.org today!
Date: Sunday, 2 December 2018
Route: 7KM
Type: Fun Walk (you can racewalk, stroll walk or run too!)
Start and end point: Dataran DBKL
Rewards:
One exclusive limited edition commemorative 999 Silver coin (3 grams)
The #Move8 Walkathon is an independently organised 7KM walk for Malaysians and friends of Malaysia on Malaysia Day in conjunction with KL Car Free Morning. The Walkathon will be held on Malaysia Day, Sunday 16 September 2018 from 7am – 10am at Dataran DBKL.
Conceived and designed to move two million Malaysians by 2020, the #Move8 Walkathon for Malaysia Dayis the first in a series of Walkathons.
Walking is a low intensity exercise which means everyone of all ages and fitness levels are welcomed to join us.
Come join us:
When: Sunday, 16 September 2018 (Malaysia Day)
Time: 7.00am – 10.00am
Where: Dataran DBKL
Fee: RM50
You can register your participation in two (2) ways:
— Partnership Focused on Providing Medical Aesthetics Consumer Education, Consultation, and Treatment Packages with Partnering Hospitals Across China —
— Designed to Further Guide Chinese Consumers to Choose Qualified Medical Aesthetics Hospitals, Doctors and Products in Pursing Beauty —
— Creates Unique Synergy between Allergan’s Leading Medical Aesthetics Brands and Alibaba Health’s Online Influence and Reach with Medical Aesthetics Consumers in China —
BEIJING, Sept. 13, 2018 /PRNewswire/ — Allergan, a global biopharmaceutical company and leader in medical aesthetics, and Alibaba Health, the flagship platform of Alibaba in the healthcare sector, announced that they have formed a strategic partnership to launch a medical aesthetics consumer education and consultation platform for the Chinese market.
Representatives of Allergan and Alibaba Health conduct strategic partnership signing
Through the partnership, Allergan and Alibaba Health aim to propel the use of appropriate medical aesthetics consultation and treatment via a sustainable medical aesthetics ecosystem in China. The two companies will leverage mobile internet and artificial intelligence to integrate competitive medical aesthetics resources and explore the online-to-offline (O2O) model across China.
The partnership will be officially launched at the end of September, through an Allergan-branded web page on the Alibaba Health platform. Through the page, consumers can access professional online medical aesthetics consultations and make online appointments for treatment packages of Allergan-branded medical aesthetics products offered by partnering hospitals and clinics.
Jason Smith, Allergan Senior Vice President and President of APAC MEA, said, “Together, Allergan and Alibaba Health are taking an important step to create a digital platform that will advance appropriate consultation and selection for Chinese consumers of medical aesthetic treatment. Through the platform, tens of millions of Chinese consumers will be properly guided to choose qualified products and treatments at accredited hospitals and have appropriate consultations with well-trained healthcare professionals.”
Leveraging Alibaba Health’s Digital Consumer Platform to Propel Medical Aesthetics Consumption Across the Chinese Market
The global expansion of internet and digital technologies in recent years is having an increasingly strong impact on China’s healthcare industry, driving massive growth in China’s healthcare consumption capacity. According to the Boston Consulting Group’s (BCG) “China’s Digital Healthcare Market Transformation” report[1], China’s digital healthcare market will grow exponentially in the coming years. From 2014 to 2020, the expenditure scale of applied digital healthcare services and healthcare e-commerce is set to increase to USD 102.6 billion from USD 293 million.
The trend is more apparent in the medical aesthetics segment, with strong growth across younger consumer groups. From 2013 to 2017, the growth rate of annual average transactions on medical aesthetics apps exceeded 200%[2]. According to Alibaba Health, GMV (gross merchandise volume) generated from the medical aesthetics segment increased by 520% year-on-year, during Alibaba’s 2017 “11.11” Global Shopping Festival.
Online portals and mobile apps, including Alibaba Health, focused on medical aesthetics are quickly emerging and attracting tens of millions of users in China. The medical device and medical healthcare services segment of Alibaba Health’s platform alone has 85.5 million active users and an established ecosystem with medical aesthetics hospitals and clinics as partners.
“Alibaba Health recently launched an online medical aesthethics service platform to explore new ways to support the increased demand for ‘quality consumption’ in medical aesthetics,” said Zhong Congdi, head of global medical consumerism at Alibaba Health. “This new cooperation with Allergan, a leading global pharmaceutical and medical aesthetics company, will achieve comprehensive integration of both partners’ advantageous resources, enabling us to provide transparent and authentic medical aesthetics information, as well as safe and effective medical aesthetics solutions for China’s consumers.”
Collaborating with Value Chain Partners for a “Healthy China”
This strategic collaboration with Alibaba Health is also a significant move by Allergan in cooperating with partners in the industrial chain and building a sustainable medical aesthetics ecosystem. China’s medical aesthetics industry is growing explosively. According to Deloitte’s “China’s Medical Aesthetics Market Analysis 2017″ report[3], China’s medical aesthetics market will reach 20.6 billion USD by 2020.
With challenges arising in the medical aesthetics industry in the face of this growth, the National Health and Family Planning Commission and six other departments jointly issued the “Special Action Plan to Combat Illegal Medical Aesthetics” in 2017, which built a sound, longterm mechanism and effectively safeguarded consumer rights and interests.
Against this backdrop, the strategic partnership will fully leverage Alibaba Health’s influence and expertise in the online medical aesthetics sector to reach large Chinese consumer groups, while Allergan will provide them with transparent and authentic medical aesthetics information to guide them in choosing qualified medical aesthetics institutions, doctors and products in pursuing beauty. For instance, Botox® customers will be able to verify the authenticity of their products with the tracking service powered by Alibaba Health, scanning the drug traceability code on the Botox® package in the Taobao, Alipay or Alibaba Health apps.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
About Alibaba Health
Alibaba Health (00241.HK) is the healthcare flagship and a subsidiary of Alibaba Group. Driven by the Double H strategy (Health and Happiness), it leverages Alibaba Group’s strengths in e-commerce, technologies and cloud computing to offer customers and healthcare industry players comprehensive online solutions that facilitate the cross-regional sharing of social healthcare resources, enhance the efficiency of medical care and promote easier access to medicine.
Alibaba Health’s current business focus is on pharmaceutical e-commerce, intelligent medicine and product tracking.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
LE-MONT-SUR LAUSANNE, Switzerland, September 13, 2018 /PRNewswire/ —
Mr. Antoine Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Platelet Rich Plasma (PRP), Bone Marrow Concentrate (BMC) and Hyaluronic Acid (HA) technologies:
Systems/methods combining PRP and HA: U.S. Patent No. 10,052,349 and
Systems for the preparation of PRP and BMC, in particular tubes containing a thixotropic gel and anticoagulant: U.S. Patent No. 10,064,894.
This brings a total of six U.S. granted patents with US8,529,957, US9,833,478, US9833478, US8,945,537 and US9,517,255 on these technologies, expanding RegenLab’s patent portfolio along with patents also recently granted in other jurisdictions (see figure below).
All these new patents represent a recognition by the USPTO of RegenLab’s innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies that RegenLab maintains its legal actions for the respect of its intellectual property rights. The stars are shining for RegenLab’s team and its future.
About RegenLab
RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLAB® and REGENKIT® brands. RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights.
PASADENA, California, Sept. 11, 2018 /PRNewswire/ — This September marks iHerb’s 22nd year of serving customers around the world. To celebrate, iHerb is offering its customers a 22% discount on a different product or category every day for the month of September.
iHerb 22nd Anniversary
“iHerb continues to innovate on behalf of customers around the world with the highest quality products, offered at the best possible value, delivered with the most convenient customer experience.”
In 1996 iHerb began selling St. John’s Wort to customers as a natural approach to ease symptoms of depression. Since then, iHerb has grown into one of the top global e-commerce companies offering the best overall value in natural products to millions of customers around the world.
Today, iHerb offers over 30,000 products from over 1,200 top global name brands in many popular categories including vitamins, supplements, health, and beauty. iHerb ensures high product quality and freshness with its GMP certified state-of-the-art climate controlled distribution centers.
“Product quality is important to customers around the world. Our iTested program represents our commitment to meet our customer needs with transparency and assurance of high-quality standards at every stage of production in our family of brands.”
iHerb values its customers through its on-going investment in the iHerb Rewards and Customer Loyalty programs. iHerb has been ranked #1 in retail Customer Satisfaction*, providing 24/7 customer support in 11 different languages to a global customer base in over 150 countries. Customers can download the iHerb app to shop conveniently on their smartphones. Orders on iHerb are delivered to customers within 1-3 days in the US and 3-5 business days globally.
About iHerb: iHerb is one of the largest US-based e-commerce retailers offering 30,000 products from 1,200 top brands to millions of customers around the world. iHerb ships directly from GMP certified, state-of-the-art climate controlled warehouses to customers in over 150 countries. Since 1996, iHerb has continued to innovate in bringing the highest quality products, at the best possible value, delivered with the most convenient customer experience. https://www.iherb.com/
MACAU, Sept. 10, 2018 /PRNewswire/ — Sands China Ltd. is launching myFITNESS, a new initiative aimed at encouraging good habits for team members’ health, physical fitness and well-being.
Sands China Ltd. President Dr. Wilfred Wong addresses team members dining at The Venetian Macao’s back-of-house team member dining room during Green Mondays – part of the company’s new myFITNESS initiative aimed at encouraging good habits for team members’ health, physical fitness and well-being
Nutritionists, traditional Chinese medicine practitioners, doctors, and nurses at The Venetian Macao’s back-of-house health booth offer personalised health advice for Sands China team members based on their current health conditions, as part of the company’s new myFITNESS initiative aimed at encouraging good habits for team members’ health, physical fitness and well-being.
The first campaigns under myFITNESS are Green Mondays and a back-of-house health booth, which encourage team members to eat a more plant-based diet in support of better health and provide team members with health advice.
“Sands China is very pleased to introduce this new programme for our team members, which encourages a healthy lifestyle,” said Dr. Wilfred Wong, president of Sands China Ltd. “Our company has been a pioneer in green initiatives, such as in the construction of our properties and the efficiency of our operations. Now we are glad to encourage that same eco-consciousness with this new team member initiatives. And with more than 28,000 team members working for the company, this important initiative can potentially influence the green eating habits of more than 28,000 families.”
During Green Mondays, the back-of-house team member dining rooms at all Sands China properties will be serving more vegetables on Mondays, with a separate vegetarian counter offering six healthy choices, including innovative plant-based meat alternatives Omnipork and Beyond Meat.
The new initiative is being done in collaboration with Green Monday, a social enterprise group that promotes green, healthy and sustainable living globally. The joint effort also supports Sands China’s efforts to reduce its carbon footprint as part of Sands ECO360, the global sustainability strategy of parent company Las Vegas Sands Corp. Encouraging team members to eat less meat is more sustainable for the environment and helps fulfil the company’s social and environmental responsibilities.
With Sands China providing daily meals for its over 28,000 team members, their participation in Green Mondays is expected to greatly reduce meat consumption, in turn decreasing carbon dioxide emissions by about 25 tons a day — equalling a 1,300-ton reduction in carbon dioxide over the course of a year.
The new myFITNESS initiative is part of Sands China’s effort to promote team member well-being by encouraging a holistic approach to health and wellness. This month’s back-of-house health booth provides team members with information about health indexes, maintaining a balanced diet, nurturing wellness, and developing good exercise habits. Nutritionists, traditional Chinese medicine practitioners, doctors, and nurses at the booth offer personalised health advice for team members based on their current health conditions. The booth also features giveaways, including healthy herbal tea packs and other items. Team members have shown enthusiasm toward understanding their health; on launch day, close to 800 team members took on-site blood pressure and blood glucose measurements. The health booth will be held for two weeks at all properties, continuing to provide team members with important health information.
And to promote regular exercise as a healthy lifestyle habit for a more fulfilling work-life balance, myFITNESS will offer exercise classes for team members in the near future.
Sands China views its team members as its greatest asset; myFITNESS is part of the company’s ongoing efforts to foster a positive and supportive work environment for its more than 28,000 team members, and to make Sands China Macao’s employer of choice.
AboutSands China Ltd. Sands China Ltd. (HKEx: 1928, Sands China or the Company) is a Cayman Islands registered company and is listed on The Stock Exchange of Hong Kong Limited. Sands China is the largest operator of integrated resorts in Macao. The Company’s Cotai Strip portfolio is comprised of The Venetian®Macao, The Plaza®Macao, Sands® Cotai Central and The Parisian Macao. The Company also owns and operates Sands®Macao on the Macao peninsula. The Company’s integrated resorts contain a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at the Cotai Arena, The Venetian Theatre, The Parisian Theatre and the Sands Cotai Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company’s Cotai Strip portfolio has the goal of contributing to Macao’s transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).
Novartis and Mundipharma, have signed an agreement for the marketing, sales and distribution of well-known pain medicine brands Voltaren® (diclofenac sodium) and Cataflam® (diclofenac potassium) in Malaysia, Thailand, and the Philippines.
Novartis will retain all international development responsibility, as well as clinical development activities. The company will also continue to manufacture and supply Voltaren® and Cataflam® for commercial use.
SINGAPORE, Sept. 10, 2018 /PRNewswire/ — International healthcare organizations, Novartis and Mundipharma, have signed an agreement for the marketing, sales and distribution of well-known pain medicine brands Voltaren® (diclofenac sodium) and Cataflam® (diclofenac potassium) in Malaysia, Thailand, and the Philippines.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, swelling (inflammation), and joint stiffness caused by arthritis. It is available as a tablet, injectable and liquid capsule.
Mundipharma Southeast Asia GM, Suresh Pragasam, said: “These medicines strategically complement our existing portfolio very well. We are now able to help provide relief for people suffering across the full pain spectrum — from mild to moderate to severe.“
“We are delighted to have partnered with Novartis in Southeast Asia on these agreements. The deal enables us to make these world-class medicines more accessible to people in three more emerging markets, where there is not the same accessibility to medicine as there is in more mature economies. This is an example of the core Mundipharma mission in action.”
“Our partnership with Mundipharma is aligned with our mission to improve patients’ quality of life and bend the curve of patient outcomes,” said Alexis Serlin, Head of Asia Cluster, Novartis AG. “The Novartis commitment to enhance healthcare providers and institutions’ access to effective medicines will be complemented by Mundipharma’s core strengths in anesthesia and surgicals in Southeast Asia.”
Novartis will retain all international development responsibility, as well as clinical development activities. The company will also continue to manufacture and supply Voltaren® and Cataflam® for commercial use.
About Mundipharma Mundipharma is a network of independent associated companies which are privately owned entities covering pharmaceutical markets in Asia-Pacific, Latin America, the Middle East and Africa. The headquarters for these territories is in Singapore. Mundipharma is a prime example of an organization that consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.
SEOUL, South Korea, Sept. 10, 2018 /PRNewswire/ — The Korea Ginseng Association (http://www.korean-ginseng.org) has provided documented data to prove the superiority of Korean Ginseng and organized a ginseng festival which will take place from October 5 to 28 in key regions across South Korea.
A Korean Fresh Ginseng
Korean Ginseng was proved in a research in 2002 done by the Chung-Ang University Ginseng Industrial Research Center to have higher levels of the six main active nutrients — G-Rb2, G-Rh1, Ge, G-Rg1, G-Rf and Se — in a study comparing ginseng from Korea, Japan, Canada and China.
Rural Development Administration have also released the results of a 10-year research study in 2017, letting the public know of the effects of Korean Ginseng.
90 test subjects with no cognitive disorders were ordered to take 3 grams of ginseng powder for 6 months — after which their visual learning and memory ability tests scored twice higher compared to those who didn’t.
70 test subjects with no cognitive disorders were ordered to take 3 grams of white ginseng powder for 12 weeks. The test subjects’ stress levels were analysed which showed an improvement in the quality of sleep and also a decrease in anxiety by 48.1%.
In animal testing, ALT (alanine aminotransaminase) and AST (aspartate aminotransferase) levels which increase during liver failures, also decreased by 38.7% and 31.9% respectively.
Fresh Ginseng with a moisture content of more than 75% is maintained in its original form. It is usually dried, brewed into a tea, blended with milk and honey or is used in cooking for chilled vegetables, kimchi and chicken stews.
Mr. Han, manager from The Korea Ginseng Association stated: “Korean Ginseng has been proven in various tests which proves its effectiveness in the improvement of the immune system, liver damage protection, blood sugar level improvements and anti-aging. We recommend consuming ginseng in its fresh state. We are expecting high interests from overseas visitors at our ginseng festivals from the 5th until the 28th of October, in key regions across South Korea.“
NEW YORK, Sept. 5, 2018 /PRNewswire/ — Anna Cane, who is specialized in Science and Technology of olive oil, at Deoleo parent company to Bertolli has recently published an article on how to develop healthy eating habits with the aid of olive oils and below is the full article:
You are what you eat. This proverb is present for many of us throughout our lives – serving as both friend, and foe. Ultimately, the lesson is that food forms a large part of our overall health, helping balance our bodies, giving us energy, regulating our system and often preventing sickness. This universal culinary lesson also transcends cultures.
Keep it Simple
The issue is often we think of healthy food as bland and expensive. But the reality is that if we do not eat carefully, exercise regularly and take care of ourselves, the risk of developing noncommunicable diseases (NCDs), like heart disease is increased. With more than 68% of deaths worldwide caused by NCDs, the risks are very real. On the other hand, if you proactively invest into your health, you can live your life, enjoy traveling, being with your family or doing what you love.
Healthy eating: start with a few simple changes
It’s important to think of healthier eating as small steps that lead to greater change. An effective starting point is simply looking at the oil you cook with. From a nutritionist’s point of view, using the right kind of oil is profitable for your health.
Olive oil, the natural oil extracted from olives, is internationally considered one of the healthiest cooking oil options. What makes it great, is that its health benefits allow us to continue enjoying our favorite foods, without radical deviations to lifestyle, or taste. And here is why:
Bertolli Olive oil
1. Olive oil can help lower cholesterol
Olive oil is naturally cholesterol-free and contains no salt. It is also rich in monounsaturated fatty acids (77% on average), in particular oleic acid which health studies indicate can help maintain normal cholesterol levels by eating this in moderation. And thereby reduce the risk of developing diseases related to high cholesterol.
2. Good source of Antioxidants
Antioxidants work by slowing or even preventing the harmful activity of ‘free radicals’ in our bodies, and Extra Virgin olive oil is a great source of several. One tablespoon of olive oil provides 8% of the recommended dietary allowance (RDA) for Vitamin E, which is linked to lessening our cell’s aging process. Likewise, olive oil contains polyphenols, another class of natural antioxidants not found in any other oil, that has beneficial properties to protect against cardiovascular disease and diabetes.
3. Olive oil can guard against cardiovascular disease
Olive oil has a higher amount of monounsaturated fatty acid (MUFA) than other vegetable oils. MUFAs are considered a healthy plant-based fat and because of olive oil’s increased levels of monounsaturated fatty acids, they help maintain normal cholesterol levels when replacing saturated fats in the diet. This helpful ingredient can also help strengthen blood vessels, protect against Alzheimer’s, lower your risk of heart disease and provide nutrients to help maintain your body’s cells.
4. Olive oil consumption can lower the risk of diabetes
Diabetes has become a large health issue in the world today, with data from the International Diabetes Federation[1] indicating that 425 million people globally are living with diabetes. According to The Center for Disease Control and Prevention (CDC)[2], in the United States there are currently 30.3 million people living with diabetes (9.4% of the population).
With olive oil’s abundance of antioxidants, it can help reduce oxidative stress effects that diabetics suffer due to elevated levels of blood sugar. It therefore reduces the risk of diabetes complications, as well as nerve damage caused by diabetes (diabetic neuropathy) and retinal neuropathy. And Oleocanthal, a type of natural phenolic compound found in extra-virgin olive oil, acts as anti-inflammatory agent. Inflammation is another precursor to many diseases, including chronic inflammation caused by diabetes.
The Bottom Line:
The health benefits of replacing bad fats with olive oil are plentiful and an easy way to start being healthier. Olive Oil is also versatile and can be utilized at high temperatures (468 degrees Fahrenheit / 242 degrees Celsius), so you can cook all your favourite dishes. Best of all, it provides you the opportunity for healthier living without boredom or huge lifestyle changes.
In 2018, it is time to make ‘you are what you eat’ your friend once again.
